Daily Research Report



T2

53985

49074

Dt.: 18th Nov. 2024

INDEX	NIFTY	BANKNIFTY	USDINR
Outlook	Neutral	Neutral	Neutral

INSTITUTIONAL TRADING ACTIVITY IN CRS.

Category	Buy Value	Sell Value	Net Value
FII	13,003.06	14,852.93	-1,849.87
DII	10,200.35	7,718.54	+2,481.81

TRADE STATISTICS FOR 14/11/2024

Instrument	No. of Contracts	Turnover (Cr.)	Put Call Ratio
Index Fut.	410095	26508.05	
Stock Fut.	1290834	83763.23	
Index Opt.	641475078	38493209	1.05
Stock Opt.	6743118	454230.6	
F&O Total	649919125	39057711	

Nifty Action: 14/11/2024



PIVOT TABLE							
	R2	R1	PIVOT	S1	S2		
NIFTY	24003	23785	23540	23317	23055		
BANKNIFTY	53785	52586	50150	49658	48785		

NIFTY FUT.			BANK NIFTY FUT.			
	TRIGGER	T1	T2		TRIGGER	T1
Above	24000	24068	24189	Above	52700	53282
Below	23350	23258	22785	Below	50000	49785



Post the Nifty's 9% correction has found support near its 200-day moving average (23,500), coinciding with a key channel pattern. Weak global cues, a strong dollar index, record-low rupee levels, high inflation, and foreign investor outflows have driven the decline. However, a positive RSI divergence hints at weakening bearish momentum, though a clear reversal is yet to be confirmed. Options data indicates a range-bound outlook of 23,300-23,700, with strong resistance at 24,000, reflecting cautious sentiment. India VIX cooling from 19 to 13 suggests reduced selling pressure and potential stabilization. The Nifty is expected to consolidate within the 23,300-24,000 range in the short term. Traders can leverage long-short strategies, focusing on range plays, with leverage longs activated only above 24,140. Investors can use this correction to accumulate oversold mega-cap stocks displaying relative strength, positioning for a potential recovery as market conditions stabilize further.

Trade Scanner: ASTRAL, BERGER PAINTS, CHOLA FINANCE, DALMIA BHARAT, HAVELLS, HUL, ITC, IRCTC, INDAN HOTEL, LTTS, NAUKRI, OFSS, ONGC, TCS, TITAN. ABB, ABFRL, BAJAJ-AUTO, BANDHANBANK, DLF, EXIDE, GRANUALS, INDIGO, JSW STEEL, LIC HSG. FINANCE, LUPIN, TORRENT PHARMA.

RESEARCH DESK: Sacchitanand Uttekar - VP - Research (Derivatives & Technicals)

Disclaimer: Investments in securities market are subject to market risk, read all the related documents carefully before investing.

Disclaimer: This document is for private circulation and information of a private circulation and information of a private circulation and information of a private circulation of any offer to buy or sell the Equity derivatives mentioned herein. We and our affiliates group? companies, directors and employees, and directors and employees of our affiliates and group? companies, including persons involved in the preparation or issuance of this material may (a) have positions which might have conflicting interest with respect to any related information. The information contained hereby may have been taken from sources which we believe are reliable. We do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinion expressed reflects judgments at this date and are subject to change without notice. Risk of loss in Equity derivatives trading can be substantial. Persons trading in Equity Derivatives should consider the suitability of trading based upon their resources, risk appetite and other relevant information, and understand that statements regarding future prospects may not be realized





